These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38370837)

  • 1. XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants.
    Jain S; Kumar S; Lai L; Linderman S; Malik AA; Ellis ML; Godbole S; Solis D; Sahoo MK; Bechnak K; Paredes I; Tanios R; Kazzi B; Dib SM; Litvack MB; Wimalasena ST; Ciric C; Rostad C; West R; Teng IT; Wang D; Edupuganti S; Kwong PD; Rouphael N; Pinsky BA; Douek DC; Wrammert J; Moreno A; Suthar MS
    bioRxiv; 2024 Feb; ():. PubMed ID: 38370837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents.
    Abul Y; Nugent C; Vishnepolskiy I; Wallace T; Dickerson E; Holland L; Esparza I; Winkis M; Wali KT; Chan PA; Baier RR; Recker A; Kaczynski M; Kamojjala S; Pralea A; Rice H; Osias O; Oyebanji OA; Olagunju O; Cao Y; Li CJ; Roederer A; Pfeifer WM; King CL; Bosch J; Nanda A; McNicoll L; Mujahid N; Raza S; Tyagi R; Wilson BM; White EM; Canaday DH; Gravenstein S; Balazs AB
    medRxiv; 2024 Mar; ():. PubMed ID: 38585784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.
    Wang Q; Guo Y; Bowen A; Mellis IA; Valdez R; Gherasim C; Gordon A; Liu L; Ho DD
    Cell Host Microbe; 2024 Mar; 32(3):315-321.e3. PubMed ID: 38377995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    Soudani N; Bricker TL; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Davis-Gardner M; Suthar MS; Ellebedy AH; Boon ACM
    J Virol; 2024 Oct; 98(10):e0052824. PubMed ID: 39230305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.
    Wang Q; Mellis IA; Guo Y; Gherasim C; Valdez R; Gordon A; Ho DD; Liu L
    Cell Rep Med; 2024 Sep; 5(9):101701. PubMed ID: 39208800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
    Patel N; Trost JF; Guebre-Xabier M; Zhou H; Norton J; Jiang D; Cai Z; Zhu M; Marchese AM; Greene AM; Mallory RM; Kalkeri R; Dubovsky F; Smith G
    Sci Rep; 2023 Nov; 13(1):19176. PubMed ID: 37932354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.
    Wang W; Bhushan G; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Pollett SD; Mitre E; Katzelnick LC; Weiss CD
    J Virol; 2024 Nov; 98(11):e0094824. PubMed ID: 39365051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
    Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
    Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.
    Wang W; Bhushan GL; Paz S; Stauft CB; Selvaraj P; Goguet E; Bishop-Lilly KA; Subramanian R; Vassell R; Lusvarghi S; Cong Y; Agan B; Richard SA; Epsi NJ; Fries A; Fung CK; Conte MA; Holbrook MR; Wang TT; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    bioRxiv; 2024 Apr; ():. PubMed ID: 38712124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2.
    Thimmiraju SR; Adhikari R; Villar MJ; Lee J; Liu Z; Kundu R; Chen YL; Sharma S; Ghei K; Keegan B; Versteeg L; Gillespie PM; Ciciriello A; Islam NY; Poveda C; Uzcategui N; Chen WH; Kimata JT; Zhan B; Strych U; Bottazzi ME; Hotez PJ; Pollet J
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
    He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
    MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting human monoclonal antibody responses from mRNA- and protein-based XBB.1.5 COVID-19 monovalent vaccines.
    Fantin RF; Clark JJ; Cohn H; Jaiswal D; Bozarth B; Civljak A; Rao V; Lobo I; Nardulli JR; Srivastava K; Yong J; Andreata-Santos R; Bushfield K; Lee ES; Singh G; ; Kleinstein SH; Krammer F; Simon V; Bajic G; Coelho CH
    bioRxiv; 2024 Jul; ():. PubMed ID: 39071292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
    Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
    Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants.
    Planas D; Peng L; Zheng L; Guivel-Benhassine F; Staropoli I; Porrot F; Bruel T; Bhiman JN; Bonaparte M; Savarino S; de Bruyn G; Chicz RM; Moore PL; Schwartz O; Sridhar S
    Heliyon; 2024 Mar; 10(5):e27033. PubMed ID: 38486776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients.
    Zhang L; Yang J; Lai C; Wan L; Xiong S; Kong W; Liu Z; Yu P; Chen M; Mai W; Khan SA; Deng M; Chen L; Lei Y; Zhou Q; Yu N; Li P; Chen Z; Ji T
    Front Immunol; 2022; 13():1042784. PubMed ID: 36700230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
    Sano K; Kurosawa T; Horikawa K; Kimura Y; Goto A; Ryo A; Hasegawa H; Kato H; Miyakawa K
    Vaccine; 2024 Dec; 42(26):126452. PubMed ID: 39418690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters.
    Ying B; Darling TL; Desai P; Liang CY; Dmitriev IP; Soudani N; Bricker T; Kashentseva EA; Harastani H; Schmidt AG; Curiel DT; Boon ACM; Diamond MS
    bioRxiv; 2023 May; ():. PubMed ID: 37205450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
    J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.